Posted by Michael Wonder on 19 Sep 2022
Ascendis Pharma submits TransCon PTH new drug application to the US FDA for adult patients with hypoparathyroidism
31 August 2022 - European MAA on track for Q4, 2022 submission.
Ascendis Pharma today announced it has submitted a New Drug Application to the US FDA for TransCon PTH, an investigational pro-drug designed to restore parathyroid hormone) to physiological levels over 24 hours in adult patients with hypoparathyroidism.
